LEADER 01587nam  2200421Ia 450 
001 9910699051203321
005 20090821133637.0
035   $a(CKB)5470000002399374
035   $a(OCoLC)432321584
035   $a(EXLCZ)995470000002399374
100   $a20090821d2004      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eIND exemptions for studies of lawfully marketed drug or biological products for the treatment of cancer
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2004]
215   $a1 online resource (8 pages)
300   $a"Center for Biologics Evaluation and Research (CBER)."
300   $a"Clinical medical."
300   $a"Revision 1."
300   $a"January 2004."
517   $aGuidance for industry 
606   $aMedicine, Experimental$xGovernment policy$zUnited States
606   $aClinical trials$xGovernment policy$zUnited States
606   $aCancer$xTreatment$zUnited States
615  0$aMedicine, Experimental$xGovernment policy
615  0$aClinical trials$xGovernment policy
615  0$aCancer$xTreatment
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699051203321
996   $aGuidance for industry$93434577
997   $aUNINA